Immuneering Corporation announced on March 20, 2025, that Dr. Igor Matushansky has joined the company as Chief Medical Officer. In this role, Dr. Matushansky will direct Immuneering’s clinical activities, providing medical and operational leadership for its development programs.
Dr. Matushansky brings extensive oncology drug development expertise, having previously served as Chief Medical Officer at Sail Biomedicines and SVP and Global Head of Oncology Development at Ipsen Pharmaceuticals. At Ipsen, he oversaw the completion of the NAPOLI-3 trial, which led to the approval of NALIRIFOX for first-line pancreatic cancer.
His appointment comes as Immuneering plans to present updated data from its Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 and prepares for the initiation of a pivotal Phase 3 clinical trial in pancreatic cancer. This leadership addition is expected to be instrumental in advancing IMM-1-104 through late-stage development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.